Real-time Artificial Intelligence-based Endocytoscopic Diagnosis of Colorectal Neoplasms
NCT ID: NCT06335654
Last Updated: 2025-12-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
680 participants
OBSERVATIONAL
2024-04-01
2024-12-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of the Diagnostic Performance of Different Artificial Intelligence Assisted Endocytoscopy for Colorectal Lesions
NCT06982872
Clinical Study on the Diagnosis of Colorectal Lesions by Real-time Artificial Intelligence Assisted Endocytoscopy Combined With Narrow Band Imaging
NCT06982885
Young-onset Colorectal Cancer Screening Based on Artificial Intelligence
NCT06342622
Early Screening of Colorectal Cancer Based on Plasma Multi-omics Combining With Artificial Intelligence
NCT05587452
Artificial Intelligence in Colonoscopy
NCT06786793
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Therefore, EndoBRAIN, as an artificial intelligence system for assisting in the diagnosis of the endocytoscopy, has the advantage of rapid diagnosis. In the EC-NBI mode, it predicts as "Non-neoplastic" or "Neoplastic", and in the EC-stained mode, its prediction result is "Non-neoplastic", "Adenoma" or "Invasive cancer".
However, currently this artificial intelligence-assisted diagnostic system has not been applied in the Chinese population. The investigators plan to conduct a prospective clinical trial to validate the accuracy of EndoBRAIN for prediction of colorectal lesions histology in real-time endocytoscopy. This study will prospectively collect the lesions that meet the inclusion and exclusion criteria. After the endoscopic doctors make the diagnosis through endoscopic optics and EndoBRAIN, and then undergo endoscopic resection or surgical resection followed by pathological diagnosis, they will compare the doctor's diagnosis, the artificial intelligence diagnosis results with the gold standard pathological results, and summarize the diagnostic accuracy of this artificial intelligence-assisted diagnostic system for the colorectal lesions.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with one or more colorectal lesions detected
During endocytoscopy, the Clinician inspect for the presence of colorectal lesions as per routine clinical practice with the EndoBRAIN turned off. When a colorectal lesion is encountered, the Clinician will make a prediction on the histology based on routine clinical practice. Following this, the EndoBRAIN function will be switched on and the Clinician will take note of the EndoBRAIN prediction for the every image of colorectal lesion.
In addition, other colorectal lesion features such as the size, location and shape will be recorded, which is similar to what is performed in routine clinical practice. The colorectal lesion will be resected and sent for pathological examination, which will form the "gold standard" for the diagnosis of colorectal lesion histology.
artificial intelligence system
The colorectal lesions had been observed with EC-NBI and EC-stained by endoscopists before treatment that were ultimately performed histopathologic examination. The endocytoscopies (CF-H290ECI, Olympus, Tokyo, Japan) have a maximum magnification of ×520, focusing depth, 35 μm; field of view, 570 × 500μm. During EC-NBI , the endoscopist pushed the button of the endoscope to switch from white-light imaging to NBI and observed the lesion with full magnification. After endocytoscopic observation, the artificial intelligence system will be open and display the predictive result. Finally, the endoscopist performed EC-stained mode diagnosis after staining the lesion surface with 1.0% methylene blue. After endocytoscopic observation, the artificial intelligence system will be open again and display the predictive result.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
artificial intelligence system
The colorectal lesions had been observed with EC-NBI and EC-stained by endoscopists before treatment that were ultimately performed histopathologic examination. The endocytoscopies (CF-H290ECI, Olympus, Tokyo, Japan) have a maximum magnification of ×520, focusing depth, 35 μm; field of view, 570 × 500μm. During EC-NBI , the endoscopist pushed the button of the endoscope to switch from white-light imaging to NBI and observed the lesion with full magnification. After endocytoscopic observation, the artificial intelligence system will be open and display the predictive result. Finally, the endoscopist performed EC-stained mode diagnosis after staining the lesion surface with 1.0% methylene blue. After endocytoscopic observation, the artificial intelligence system will be open again and display the predictive result.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* consent obtained for the study
Exclusion Criteria
* a history of inflammatory bowel disease
* chemotherapy or radiation therapy for colorectal cancer
* lesions without clear EC images
* specific pathological types
* familial adenomatous polyposis
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The First Hospital of Jilin University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hong Xu
Director, Head of Gastroenterology and Endoscopy Center, Principal Investigator, Clinical Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hong Xu, PHD
Role: PRINCIPAL_INVESTIGATOR
The First Hospital of Jilin University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First hospital of Jilin University
Changchun, Jilin, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
24K056-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.